{"id":21130,"date":"2025-04-08T15:59:12","date_gmt":"2025-04-08T08:59:12","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=21130"},"modified":"2025-04-08T15:59:12","modified_gmt":"2025-04-08T08:59:12","slug":"micurx-15-clinical-and-preclinical-research-studies-to-be-presented-at-escmid-global-2025","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=21130","title":{"rendered":"MicuRx: 15 Clinical and Preclinical Research Studies to be Presented at ESCMID Global 2025"},"content":{"rendered":"

SHANGHAI<\/span><\/span>, April 8, 2025<\/span><\/span> \/PRNewswire\/ — The 2025 European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025) will take place in Vienna<\/span> from April 11 to 15, 2025<\/span>. As one of the largest, most comprehensive, and influential global academic conferences in the fields of clinical microbiology, infectious diseases, and infection control, ESCMID Global serves as a pivotal platform for scientific exchange. Shanghai MicuRx Pharmaceutical Co., Ltd. (“MicuRx”, Stock Code: 688373) will present 15 new clinical and preclinical research datasets related to its pipeline products in poster presentations during the conference. The presentations will focus on two core products: Contezolid and MRX-5.<\/p>\n

MRX-5: Preclinical and Phase 1 data supporting its potential as a novel treatment for nontuberculous mycobacterial (NTM) pulmonary disease, particularly Mycobacterium abscessus (MAB) infections.<\/p>\n

\n\n\n\n\n\n\n\n
\n

Title<\/span><\/p>\n<\/td>\n

\n

Category<\/span><\/p>\n<\/td>\n

\n

Time<\/span><\/p>\n<\/td>\n

\n

Location<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Pharmacokinetic\/Pharmacodynamic
Evaluation of MRX-5 in Murine Models of
Mycobacterium abscessus Pulmonary
Disease<\/span><\/p>\n<\/td>\n

\n

Oral poster
presentation<\/span><\/p>\n<\/td>\n

\n

April 12,
8:30-9:30
am<\/span><\/p>\n<\/td>\n

\n

Arena 3<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Benzoxaborole Antimycobacterial MRX-
5: Preclinical Pharmacokinetics and in
vitro Drug-Drug Interaction<\/span><\/p>\n<\/td>\n

\n

Top-rated
poster<\/span><\/p>\n<\/td>\n

\n

April 13,
12:00-13:30
pm<\/span><\/p>\n<\/td>\n

\n

\u00a0poster
area, Hall D<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

13-week Repeat-Dose Toxicology
Studies of MRX-5 in Sprague Dawley Rats
and Beagle Dogs<\/span><\/p>\n<\/td>\n

\n

Poster<\/span><\/p>\n<\/td>\n

\n

April 13,
12:00-13:30
pm<\/span><\/p>\n<\/td>\n

\n

\u00a0poster<\/span><\/p>\n

\u00a0area, Hall D<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Safety, tolerability and pharmacokinetics
of single and multiple ascending doses
and food-effect of MRX-5 tablets in
healthy adult subjects<\/span><\/p>\n<\/td>\n

\n

Poster<\/span><\/p>\n<\/td>\n

\n

April 13,
12:00-13:30
pm<\/span><\/p>\n<\/td>\n

\n

\u00a0poster
area, Hall D<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n

Four studies on MRX-5 presented at the conference<\/p>\n

“We are excited to share our latest clinical and scientific advancements at ESCMID Global 2025,” Dr. Zhengyu Yuan<\/span>, Chairman and CEO of MicuRx, stated\uff0c”These data highlighted our ongoing commitment to developing innovative therapies to address urgent unmet needs in infectious and chronic pulmonary diseases.”<\/p>\n

MicuRx invites attendees to visit the poster sessions to engage with the team and learn more about the company’s clinical progress and future development plans.<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n

SHANGHAI<\/span><\/span>, April 8, 2025<\/span><\/span> \/PRNewswire\/ — The 2025 European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025) will take place in Vienna<\/span> from April 11 to 15, 2025<\/span>. As one of the largest, most comprehensive, and influential global academic conferences in the fields of clinical microbiology, infectious diseases, and infection control, ESCMID Global serves as a pivotal platform for scientific exchange. Shanghai MicuRx Pharmaceutical Co., Ltd. (“MicuRx”, Stock Code: 688373) will present 15 new clinical and preclinical research datasets related to its pipeline products in poster presentations during the conference. The presentations will focus on two core products: Contezolid and MRX-5.<\/p>\n

MRX-5: Preclinical and Phase 1 data supporting its potential as a novel treatment for nontuberculous mycobacterial (NTM) pulmonary disease, particularly Mycobacterium abscessus (MAB) infections.<\/p>\n

\n\n\n\n\n\n\n\n
\n

Title<\/span><\/p>\n<\/td>\n

\n

Category<\/span><\/p>\n<\/td>\n

\n

Time<\/span><\/p>\n<\/td>\n

\n

Location<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Pharmacokinetic\/Pharmacodynamic
Evaluation of MRX-5 in Murine Models of
Mycobacterium abscessus Pulmonary
Disease<\/span><\/p>\n<\/td>\n

\n

Oral poster
presentation<\/span><\/p>\n<\/td>\n

\n

April 12,
8:30-9:30
am<\/span><\/p>\n<\/td>\n

\n

Arena 3<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Benzoxaborole Antimycobacterial MRX-
5: Preclinical Pharmacokinetics and in
vitro Drug-Drug Interaction<\/span><\/p>\n<\/td>\n

\n

Top-rated
poster<\/span><\/p>\n<\/td>\n

\n

April 13,
12:00-13:30
pm<\/span><\/p>\n<\/td>\n

\n

\u00a0poster
area, Hall D<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

13-week Repeat-Dose Toxicology
Studies of MRX-5 in Sprague Dawley Rats
and Beagle Dogs<\/span><\/p>\n<\/td>\n

\n

Poster<\/span><\/p>\n<\/td>\n

\n

April 13,
12:00-13:30
pm<\/span><\/p>\n<\/td>\n

\n

\u00a0poster<\/span><\/p>\n

\u00a0area, Hall D<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Safety, tolerability and pharmacokinetics
of single and multiple ascending doses
and food-effect of MRX-5 tablets in
healthy adult subjects<\/span><\/p>\n<\/td>\n

\n

Poster<\/span><\/p>\n<\/td>\n

\n

April 13,
12:00-13:30
pm<\/span><\/p>\n<\/td>\n

\n

\u00a0poster
area, Hall D<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

Four studies on MRX-5 presented at the conference<\/p>\n

“We are excited to share our latest clinical and scientific advancements at ESCMID Global 2025,” Dr. Zhengyu Yuan<\/span>, Chairman and CEO of MicuRx, stated\uff0c”These data highlighted our ongoing commitment to developing innovative therapies to address urgent unmet needs in infectious and chronic pulmonary diseases.”<\/p>\n

MicuRx invites attendees to visit the poster sessions to engage with the team and learn more about the company’s clinical progress and future development plans.<\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-21130","post","type-post","status-publish","format-standard","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/21130","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21130"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/21130\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21130"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21130"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21130"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}